Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells - PubMed (original) (raw)
Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells
Xiaoping Duan et al. Clin Exp Metastasis. 2004.
Abstract
Introduction: Expression of adhesion molecules such as alphavbeta3 integrin has been associated with the metastatic potential of tumor cells. The purpose of this study was to determine whether alphavbeta3 expression correlated with the metastatic potential of human osteosarcoma cells.
Materials and methods: We developed a series of sublines (LM2-LM7) from human osteosarcoma SAOS parental cells, with progressively increasing potential to form lung metastases in nude mice after intravenous injection. SAOS parental and LM2 cells were poorly metastatic, but LM7 cells resulted in visible metastatic lung nodules by 6-8 weeks. We quantified alphavbeta3 integrin expression using flow cytometry.
Results: alphavbeta3 expression correlated with the metastatic potential of the cells, with LM7 cells showing the highest expression. LM7 cell adhesion to vitronectin decreased after treatment with echistatin, a RGD-containing peptide antagonist of alphavbeta3. LM7 cells demonstrated higher chemotactic activity than SAOS cells to a homogenate made from lung tissue. This chemotactic activity was also inhibited by echistatin. These data indicated that alphavbeta3 was critical for the migration of LM7 cells to the lung homogenate. Chemotaxis to a liver homogenate was the same for LM7 and SAOS cells. Migration of LM7 cells through lung endothelial cells was higher than that through liver endothelial cells, and echistatin again inhibited this migration.
Conclusions: alphavbeta3 integrin expression may play a role in the metastatic potential of osteosarcoma cells by enhancing the ability of the cells to migrate specifically to the lung. Alphavbeta3 integrin may therefore be a potential new target for osteosarcoma.
Similar articles
- Disintegrin targeting of an αvβ3 integrin-over-expressing high-metastatic human osteosarcoma with echistatin inhibits cell proliferation, migration, invasion and adhesion in vitro.
Tome Y, Kimura H, Kiyuna T, Sugimoto N, Tsuchiya H, Kanaya F, Bouvet M, Hoffman RM. Tome Y, et al. Oncotarget. 2016 Jul 19;7(29):46315-46320. doi: 10.18632/oncotarget.10111. Oncotarget. 2016. PMID: 27331872 Free PMC article. - Increased Fas expression reduces the metastatic potential of human osteosarcoma cells.
Lafleur EA, Koshkina NV, Stewart J, Jia SF, Worth LL, Duan X, Kleinerman ES. Lafleur EA, et al. Clin Cancer Res. 2004 Dec 1;10(23):8114-9. doi: 10.1158/1078-0432.CCR-04-0353. Clin Cancer Res. 2004. PMID: 15585647 - High lung-metastatic variant of human osteosarcoma cells, selected by passage of lung metastasis in nude mice, is associated with increased expression of α(v)β(3) integrin.
Tome Y, Kimura H, Maehara H, Sugimoto N, Bouvet M, Tsuchiya H, Kanaya F, Hoffman RM. Tome Y, et al. Anticancer Res. 2013 Sep;33(9):3623-7. Anticancer Res. 2013. PMID: 24023288 - Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.
Gordon N, Kleinerman ES. Gordon N, et al. J Aerosol Med Pulm Drug Deliv. 2010 Aug;23(4):189-96. doi: 10.1089/jamp.2009.0812. J Aerosol Med Pulm Drug Deliv. 2010. PMID: 20528149 Free PMC article. Review. - The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases.
Gordon N, Kleinerman ES. Gordon N, et al. Cancer Treat Res. 2009;152:497-508. doi: 10.1007/978-1-4419-0284-9_29. Cancer Treat Res. 2009. PMID: 20213411 Review.
Cited by
- Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach.
Schott CR, Koehne AL, Sayles LC, Young EP, Luck C, Yu K, Lee AG, Breese MR, Leung SG, Xu H, Shah AT, Liu HY, Spillinger A, Behroozfard IH, Marini KD, Dinh PT, Pons Ventura MV, Vanderboon EN, Hazard FK, Cho SJ, Avedian RS, Mohler DG, Zimel M, Wustrack R, Curtis C, Sirota M, Sweet-Cordero EA. Schott CR, et al. Clin Cancer Res. 2024 Feb 16;30(4):849-864. doi: 10.1158/1078-0432.CCR-23-0873. Clin Cancer Res. 2024. PMID: 37703185 Free PMC article. - A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells.
Talbot LJ, Chabot A, Funk A, Nguyen P, Wagner J, Ross A, Tillman H, Davidoff A, Gottschalk S, DeRenzo C. Talbot LJ, et al. Front Immunol. 2021 Jun 15;12:691741. doi: 10.3389/fimmu.2021.691741. eCollection 2021. Front Immunol. 2021. PMID: 34211478 Free PMC article. - Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression.
Fan TM, Roberts RD, Lizardo MM. Fan TM, et al. Front Oncol. 2020 Jan 31;10:13. doi: 10.3389/fonc.2020.00013. eCollection 2020. Front Oncol. 2020. PMID: 32082995 Free PMC article. Review. - Long noncoding RNA CASC11 promotes osteosarcoma metastasis by suppressing degradation of snail mRNA.
Song K, Yuan X, Li G, Ma M, Sun J. Song K, et al. Am J Cancer Res. 2019 Feb 1;9(2):300-311. eCollection 2019. Am J Cancer Res. 2019. PMID: 30906630 Free PMC article. Retracted. - Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma.
Shi K, Wang SL, Shen B, Yu FQ, Weng DF, Lin JH. Shi K, et al. World J Surg Oncol. 2019 Jan 28;17(1):23. doi: 10.1186/s12957-019-1566-z. World J Surg Oncol. 2019. PMID: 30691475 Free PMC article.
References
- N Engl J Med. 1986 Jun 19;314(25):1600-6 - PubMed
- Cancer Res. 2003 Jun 1;63(11):2971-6 - PubMed
- J Pathol. 1999 Nov;189(3):300-8 - PubMed
- Cancer Res. 2001 Mar 1;61(5):2232-8 - PubMed
- Int J Cancer. 2000 Apr 1;86(1):15-23 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical